glucagon glp-1 LY3437943, a novel triple glucagon, GIP, and receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism The Road towards Triple Agonists:

Heart rate variability in individuals with autism spectrum disorders: A meta-analysis

Moshayedi P, Nih LR, Llorente IL, Berg AR, Cinkornpumin J, Lowry WE, Segura T, Carmichael ST., "Systematic optimization of an engineered hydrogel allows for selective control of human neural stem cell survival and differentiation after transplantation in the stroke brain", Biomaterials 105: 145-155 (2016)

It also lists hydration, post-meal walking, and avoiding carbonated drinks

& Kutala, B

An FDA import alert to protect Americans At the end of May, a non-FDA unregistered company in China, Chengdu Miao Ding Xin Pharmaceutical Technology Co., Ltd., shipped nearly 10 kilograms of tirzepatide four million starting doses in three separate shipments intended for compounding (Shipment IDs: H77-0230371-7/13/1, H77-0230371-7/13/2, H77-0230371-7/13/3)

GLP-1 (Glucagon-Like Peptide-1) receptor agonists are a class of medications designed to mimic the action of the natural GLP-1 hormone in the body